Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
08/11/2022* -- Results Q2 2022 -- -0.59 --
05/10/2022 -- Results Q1 2022 -0.53 -0.51 -3.92%
03/23/2022 -- Results Q4 2021 -0.37 -0.57 35.54%
11/12/2021 -- Results Q3 2021 -0.52 -0.42 -23.81%
08/11/2021 -- Results Q2 2021 -0.43 -0.38 -14.16%
05/20/2021 -- Results Q1 2021 -3.48 -0.42 -728.6%
*Estimated Date/Time

Earnings

Next Report Date 08/11/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 05/10/2022
Beat/Miss Upgrade
Return Since -3.75%
Last FQE 03/31/2022
Next FQE 06/30/2022

Profile

Edit
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
URL https://www.reneopharma.com
Investor Relations URL N/A
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Aug. 11, 2022 (est.)
Last Earnings Release May. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
--
--
--
-72.98%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.77%
-87.17%
63.37%
16.67%
-79.93%
-17.17%
8.91%
-45.97%
-44.16%
-9.04%
-23.93%
70.05%
-17.52%
10.42%
-13.60%
-24.30%
-45.47%
-18.25%
-29.46%
-55.16%
-57.46%
-66.95%
321.7%
-47.71%
-43.19%
56.85%
-66.70%
-33.39%
-96.85%
-9.48%
-24.44%
-28.93%
-30.16%
As of June 23, 2022.

Profile

Edit
Reneo Pharmaceuticals Inc is a clinical stage pharmaceutical company. It is focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The company is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
URL https://www.reneopharma.com
Investor Relations URL N/A
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style N/A
Next Earnings Release Aug. 11, 2022 (est.)
Last Earnings Release May. 10, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RPHM Tweets